ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

Brain

Volumn 132, Issue 9, 2009, Pages 2517-2530

  Cotte, S ^a,b   Von Ahsen, N ^a   Kruse, N ^a   Huber, B ^a,b   Winkelmann, A ^c   Zettl, U K ^c   Starck, M ^d   Konig N ^d   Tellez, N ^e   Dorr J ^f   Paul, F ^f   Zipp, F ^f   Luhder F ^a   Koepsell, H ^g   Pannek, H ^h   Montalban, X ^e   Gold, R ^b   Chan, A ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d Marianne Strauss Hospital   (Germany)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h EPILEPSY CENTER BETHEL   (Germany)

Author keywords

Escalation therapy; Experimental autoimmune encephalomyelitis; Multi drug resistance transporter; Pharmacogenetics

Indexed keywords

ABC TRANSPORTER; DEXAMETHASONE; GLUCOCORTICOID; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; AGRANULOCYTOSIS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISABILITY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERMANY; GLIA CELL; HEART MUSCLE CELL; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADULT; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC MARKERS; GENOTYPE; GLUCOCORTICOIDS; HUMANS; MALE; MICE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 71549134054     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp164     Document Type: Article

References (41)

1. Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxi-city in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006; 59: 206-209.
2. Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 2008; 7: 173-183.
3. Bursch W, Paffe S, Putz B, Barthel G, Schulte-Hermann R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis 1990; 11: 847-853.
4. Chan A, Seguin R, Magnus T, Papadimitriou C, Toyka KV, Antel JP, et al. Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS-autoimmune inflammation and modulation by interferon-beta. Glia 2003; 43: 231-242.
5. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152-158.
6. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004; 63: S28-32.
7. Dörr J, Bitsch A, Schmailzl KJG, Chan A, von Ahsen N, Meyer R, et al. Severe cardiac failure in a multiple sclerosis patient following low-dose mitoxantrone treatment. Neurology 2009; in press.
8. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092-6099.
9. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylpred-nisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria [see comments]. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
10. Gaunt T, Rodriguez S, Day I. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 2007; 8: 428.
11. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909-913.
12. Gonsette RE. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 2007; 8: 1103-1116.
13. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double blind, randomised multicentre trial. Lancet 2002; 360: 2018-2025.
14. Hasan SK, Mays AN, Ottone T, Ledda A, La NG, Cattaneo C, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008; 112: 3383-3390.
15. Hermann DM, Kilic E, Spudich A, Kramer SD, Wunderli-Allenspach H, Bassetti CL. Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 2006; 60: 489-498.
16. Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293-298.
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
18. Hu OY, Chang SP, Law CK, Jian JM, Chen KY. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. Cancer 1992; 69: 847-853.
19. Kopadze T, Dehmel T, Hartung HP, Stuve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006; 63: 1572-1578.
20. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psych 2007; 79: 52-56.
21. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multi-drug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086-1099.
22. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602.
23. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004; 109: 238-246.
24. Morrissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005; 12: 74-87.
25. Paul F, Dörr J, Wü rfel J, Vogel HP, Zipp F. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007; 78: 198-200.
26. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonnker JW, et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine, and transport of cimetidine. J Pharmacol Exp Ther 2005; 312: 144-152.
27. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg 2004; 106: 147-158.
28. Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, et al. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 2004; 251: 1329-1339.
29. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007; 26: 39-57.
30. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
31. Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE, et al. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler 2004; 10 Suppl 1: S58-S61
32. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-862.
33. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203-209.
34. von Ahsen N, Lewczuk P, Schutz E, Oellerich M, Ehrenreich H. Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation. Thromb Res 2000; 99: 549-556.
35. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclos-porin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-1052.
36. Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004; 135: 49-55.
37. Wojnowski L, Kulle B, Schirmer M, Schlü ter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-3762.
38. Zamar D, McNeney B, Graham J. elrm: Software implementing exact-like inference for logistic regression models. J Stat Software 2007; 21: 1-18.
39. Zheng G. Analysis of ordered categorical data: two score-independent approaches. Biometrics 2008; 64: 1276-1279.
40. Zheng G, Freidlin G, Zhaohai L, Gastwirth JL. Choice of scores in trend tests for case-control studies of candidate-gene associations. Biometrical J 2003; 45: 335-348.
41. Zhou S, Zong Y, Lu T, Sorrentino BP. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mr1a/1b develop normally but are sensitized to mitoxantrone. BioTechniques 2003; 35: 1248-1252